Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer

Imran Khan1, Brunilde Gril1, Anurag N Paranjape1

  • 1Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

Insights

Albumin shows promise for delivering drugs to brain metastases in breast cancer. This study found albumin effectively targets both large and small metastases via a novel endocytic pathway, unlike other tested methods.

Area of Science:

  • Neuro-oncology
  • Cancer Therapeutics
  • Drug Delivery Systems

Background:

  • Current breast cancer brain metastases treatments offer limited efficacy.
  • Poor drug penetration into brain metastases via paracellular routes hinders treatment.
  • Novel strategies are needed to improve drug delivery across the blood-brain barrier.

Purpose of the Study:

  • To evaluate three transcytotic pathways for drug delivery to brain metastases.
  • To identify optimal pathways for enhanced drug distribution in brain metastases.
  • To elucidate the mechanism of albumin uptake in brain metastases.

Main Methods:

  • Far-red labeled transferrin receptor (TfR) peptide, low-density lipoprotein receptor 1 (LRP1) peptide, and albumin were injected into two brain metastases models.
  • Uptake was quantified in metastases and uninvolved brain tissue after defined circulation times.
  • Albumin endocytosis mechanism and its components were investigated in metastatic endothelial cells.

Main Results:

  • Albumin demonstrated significantly higher distribution to brain metastases compared to uninvolved brain (P < 0.0001).
  • Albumin effectively targeted both macrometastases and micrometastases.
  • A novel clathrin-independent endocytosis (CIE) pathway involving neonatal Fc receptor, galectin-3, and glycosphingolipids was identified for albumin uptake.

Conclusions:

  • Albumin represents a promising strategy for improving drug delivery to brain metastases.
  • The identified novel CIE mechanism offers a potential target for enhancing drug transport.
  • Albumin-based delivery may be applicable to other central nervous system (CNS) cancers.